Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):918–921. doi: 10.1038/bjc.1994.177

Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study.

J Brittenden 1, S D Heys 1, I Miller 1, T K Sarkar 1, A W Hutcheon 1, G Needham 1, F Gilbert 1, M McKean 1, A K Ah-See 1, O Eremin 1
PMCID: PMC1968918  PMID: 8180024

Abstract

L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and 'moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

Full text

PDF
918

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson E. D., Forrest A. P., Hawkins R. A., Anderson T. J., Leonard R. C., Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer. 1991 Apr;63(4):561–566. doi: 10.1038/bjc.1991.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. doi: 10.1093/jnci/82.19.1539. [DOI] [PubMed] [Google Scholar]
  3. Cheung C. W., Johnson A. E. Carcinoma of the breast: measurement and the management of treatment. I. The value of the data. Br J Radiol. 1991 Jan;64(757):29–36. doi: 10.1259/0007-1285-64-757-29. [DOI] [PubMed] [Google Scholar]
  4. De Lena M., Zucali R., Viganotti G., Valagussa P., Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1(1):53–59. doi: 10.1007/BF00253147. [DOI] [PubMed] [Google Scholar]
  5. Feldman L. D., Hortobagyi G. N., Buzdar A. U., Ames F. C., Blumenschein G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May;46(5):2578–2581. [PubMed] [Google Scholar]
  6. Fornage B. D., Toubas O., Morel M. Clinical, mammographic, and sonographic determination of preoperative breast cancer size. Cancer. 1987 Aug 15;60(4):765–771. doi: 10.1002/1097-0142(19870815)60:4<765::aid-cncr2820600410>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  7. Gröhn P., Heinonen E., Klefström P., Tarkkanen J. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer. 1984 Aug 15;54(4):670–674. doi: 10.1002/1097-0142(1984)54:4<670::aid-cncr2820540414>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  8. Luboinski G., Nagadowska M., Pienkowski T. Preoperative chemotherapy in primarily inoperable cancer of the breast. Eur J Surg Oncol. 1991 Dec;17(6):603–607. [PubMed] [Google Scholar]
  9. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Pain J. A., Ebbs S. R., Hern R. P., Lowe S., Bradbeer J. W. Assessment of breast cancer size: a comparison of methods. Eur J Surg Oncol. 1992 Feb;18(1):44–48. [PubMed] [Google Scholar]
  11. Park K. G., Heys S. D., Blessing K., Kelly P., McNurlan M. A., Eremin O., Garlick P. J. Stimulation of human breast cancers by dietary L-arginine. Clin Sci (Lond) 1992 Apr;82(4):413–417. doi: 10.1042/cs0820413. [DOI] [PubMed] [Google Scholar]
  12. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  13. Rodger A., Jack W. J., Hardman P. D., Kerr G. R., Chetty U., Leonard R. C. Locally advanced breast cancer: report of phase II study and subsequent phase III trial. Br J Cancer. 1992 May;65(5):761–765. doi: 10.1038/bjc.1992.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rubens R. D. The management of locally advanced breast cancer. Br J Cancer. 1992 Feb;65(2):145–147. doi: 10.1038/bjc.1992.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sorace R. A., Bagley C. S., Lichter A. S., Danforth D. N., Jr, Wesley M. W., Young R. C., Lippman M. E. The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. World J Surg. 1985 Oct;9(5):775–785. doi: 10.1007/BF01655193. [DOI] [PubMed] [Google Scholar]
  16. Swain S. M., Sorace R. A., Bagley C. S., Danforth D. N., Jr, Bader J., Wesley M. N., Steinberg S. M., Lippman M. E. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987 Jul 15;47(14):3889–3894. [PubMed] [Google Scholar]
  17. Torosian M. H., Mullen J. L., Miller E. E., Wagner K. M., Stein T. P., Buzby G. P. Adjuvant, pulse total parenteral nutrition and tumor response to cycle-specific and cycle-nonspecific chemotherapy. Surgery. 1983 Aug;94(2):291–299. [PubMed] [Google Scholar]
  18. Torosian M. H., Tsou K. C., Daly J. M., Mullen J. L., Stein T. P., Miller E. E., Buzby G. P. Alteration of tumor cell kinetics by pulse total parenteral nutrition. Potential therapeutic implications. Cancer. 1984 Mar 15;53(6):1409–1415. doi: 10.1002/1097-0142(19840315)53:6<1409::aid-cncr2820530632>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES